echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Lancet: Ad5 vector COVID-19 vaccine Phase II clinical success.

    Lancet: Ad5 vector COVID-19 vaccine Phase II clinical success.

    • Last Update: 2020-07-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    !---- researchers recently published the results of the Iegenic and Safe Phase II clinical study of the non-replicated type 5 adenovirus (Ad5) vector COVID-19 vaccineThis random, double-blind, placebo-controlled Ad5 vector COVID-19 vaccine Phase II trial was conducted in Wuhan, China, with healthy adults over 18 years of age participating in HIV-negative participants who were previously free of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, randomly received a vaccine or placebo for 1 x 1011 virus particles per milliliter, 5 x 1010 viral particlesThe main endpoint of immunogenicity is the geometric mean titer (GMT) and 28-day neutralizing antibody response of the receptor binding domain (RBD)-specific ELISA antibody responseThe main endpoint of safety evaluation was the incidence of adverse reactions within 14 days508 participants, 50% of men, with an average age of 39.7 years, were randomly vaccinated (1 x 1011 virus particle group n x 253; 5 x 1010 virus particle group n x 129) or placebo (n-126)In the 1 x 1011 and 5 x 1010 viral particle dose groups, RBD-specific ELISA antibodies peaked at 656.5 and 571.0 on the 28th day, respectively, with serum conversion rates of 96% and 97%, respectivelyBoth doses of the vaccine produced significant neutralizing antibody responses, with participants vaccinated at 1 x 1011 and 5 x 1010 virus particles at GMT of 19.5 and 18.3, respectivelyOf the 253 participants in the 1 x 1011 viral particle group, 227 were in the 5 x 1010 virus particle dose group, and 113 were observed with specific interferon-pyrasse-linked immune responses after vaccinationOf the 253 participants in the 1 x 1011 viral particle dose group, 183 (72%) and 96 (74%) of the 129 participants in the 5 x 1010 particulate dose group reported adverse reactionsSevere adverse reactions were reported by 24 (9%) participants and 1 (1%) participants in the 1 x 1011 viral particle dose group and the 5 x 1010 particle dose group, respectivelyThe study concluded that the Ad5 vector COVID-19 vaccine was safe, and that most subjects had a significant immune response after a single immunization
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.